Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of schizophrenia~* Must be an outpatient (not requiring hospitalization) now and for at least the past 8 weeks.~* Disease symptoms must meet a certain range as assessed by the clinician.~* Patient has experienced at least two episodes of clinical worsening of their condition. This could mean admission to a hospital or an emergency room visit. This could mean that a new medication was added, medication dose was increased, or medication was switched in order to better control symptoms of the condition.~* The patient must have an unsatisfactory response to their current medication or be experiencing negative effects of their current medication or not always take their current medication so that a change in current medication is desired.~Exclusion Criteria:~* Patients who are actively suicidal.~* Patients who are pregnant or nursing.~* Patients who have stopped past treatment with olanzapine because of adverse events, are treatment resistant or allergic to olanzapine, or have a condition which would prevent use of a long acting form of olanzapine.~* Patients with uncorrected narrow-angle glaucoma, seizures, uncontrolled diabetes, certain diseases of the liver, uncontrolled thyroid condition or other serious or unstable illness.~* Patients with Parkinson's disease, psychosis related to dementia or other related disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine Pamoate Depot (Type: EXPERIMENTAL): Olanzapine pamoate depot
- Olanzapine (Type: ACTIVE_COMPARATOR): Oral olanzapine

Based on this trial design, predict the completion outcome and termination type (if applicable).